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This phase II study evaluated the response rate and tolerability of gemcitabine–oxaliplatin chemotherapy in non-small-cell lung cancer
(NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000mgm
 2 on days 1 and 8, followed
by oxaliplatin 130mgm
 2 on day 1. Cycles were repeated every 21 days for up to six cycles. From February 2002 to May 2004, 60
patients were enrolled into the study in seven Italian institutions. We observed one complete response (1.7%) and 14 partial
responses (23.3%), for an overall response rate of 25.0% (95% confidence interval, 14.7–37.9%). The median duration of response
was 5.9 months (range 1.5–17.1 months). With a median follow-up of 6.7 months, median time to progressive disease and overall
survival were 2.7 (range 1.9–3.4 months) and 7.3 months (range 7.2–8.6 months), respectively. The main grade 3–4 haematological
toxicities were transient neutropenia in 11.7% and thrombocytopenia in 8.3% of the patients. Nausea/vomiting was the main grade
3–4 nonhaematological toxicity, occurring in 10.0% of the patients. Two (3.3%) patients developed grade 3 neurotoxicity. Our
results show that gemcitabine–oxaliplatin chemotherapy is active and well tolerated in patients with advanced NSCLC, deserving
further study, especially for patients not eligible to receive cisplatin.
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Non-small-cell lung cancer (NSCLC) is the leading cause of cancer
death in the world (Greenlee et al, 2001). Platinum-based
chemotherapy is considered the standard treatment for advanced
disease, with cisplatin considered the most effective for NSCLC
(Non-Small Cell Lung Cancer Collaborative Group, 1995). New
agents, such as taxanes and vinorelbine, administered with a
platinum derivative, have resulted in improved median and 1-year
survival times when compared with either cisplatin alone or older
platinum-based combinations in randomised trials (Le Chevalier
et al, 1994; Wozniak et al, 1998; Bonomi et al, 2000; Sandler et al,
2000).
Gemcitabine’s mild toxicity profile, both in terms of haemato-
logical toxicity and visceral side effects, and novel mechanism of
action have encouraged its use in combination with traditional
agents, such as cisplatin. Gemcitabine–cisplatin chemotherapy is
considered one of the most active regimens for advanced NSCLC,
with an overall response rate (ORR) of 22–38% and median
survival of 8.1–9.8 months in phase III trials (Crino ` et al, 1999;
Scagliotti et al, 2002; Schiller et al, 2002). Although several phase
III trials of new platinum-based doublets (Kelly et al, 2001;
Schiller et al, 2002; Smit et al, 2003) have produced similar
results, a recent meta-analysis showed an absolute 1-year survival
benefit of 3.9% for gemcitabine–cisplatin chemotherapy when
compared to other platinum-containing regimens (Le Chevalier
et al, 2005).
Cisplatin has been the most widely used platinum derivative, but
it is known to yield significant toxicities, including severe nausea
and vomiting, and renal toxicity, requiring adequate hydration,
ototoxicity and neuropathy. Oxaliplatin is a diaminocyclohexane
platinum compound, with a mechanism of action similar to that
of cisplatin (Woynarowski et al, 2000), that has shown activity
against a variety of cancer types, including colon (de Gramont et al,
1997) and NSCLC (Monnet et al, 1998). Oxaliplatin has a more
manageable toxicity profile than cisplatin, with no renal toxicity
and a lower incidence of haematological and gastrointestinal
toxicities. It lacks the nephrotoxicity of cisplatin and causes less
myelotoxicity than carboplatin, the leading cisplatin analog, and it
may be active in cisplatin- and carboplatin-resistant tumours
(Chollet et al, 1996; Raymond et al, 1998b). The main toxicity
associated with oxaliplatin is a generally reversible peripheral
neuropathy (Raymond et al, 1998a).
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sOxaliplatin has demonstrated synergy with gemcitabine, with a
sequence dependency that favours the administration of gemcita-
bine, followed by oxaliplatin (Faivre et al, 1999). A phase I trial,
conducted by Shibata et al (2001), investigated the maximum
tolerated dose of gemcitabine–oxaliplatin in patients with solid
tumours. This study showed that oxaliplatin 130mgm
 2 on day 1
could be safely administered with gemcitabine 1000mgm
 2 on
days 1 and 8 every 21 days. Using different schedules, other
investigators (Faivre et al, 2002; Mavroudis et al, 2003) confirmed
that gemcitabine–oxaliplatin is feasible, with no dose-limiting
toxicities, easy to administer on an outpatient basis, and shows
promising activity in patients with NSCLC and ovarian cancer.
On the basis of these data, we designed a phase II, multicentre
trial to evaluate the response rate and tolerability of gemcitabine–
oxaliplatin in untreated patients with stage IIIB or IV NSCLC,
applying the same 3-week dosing schedule as per Shibata et al.
Secondary end points were time to progressive disease (TtPD) and
overall survival (OS).
PATIENTS AND METHODS
Patient selection
Chemonaive patients with histologically or cytologically confirmed
locally advanced or metastatic stage IIIB or IV NSCLC not
amenable to surgery or radiotherapy with curative intent were
eligible for this study. Other eligibility criteria included the
presence of at least one measurable lesion; age X18 to p75 years;
Karnofsky performance status (KPS) X70, life expectancy X12
weeks; adequate bone marrow reserve (absolute neutrophil count
X2.0 10
9l
 1, platelet count X100 10
9l
 1). Patients with asympto-
matic brain metastases were eligible. No prior chemotherapy or
immunotherapy or concomitant radiotherapy was allowed. Prior
radiotherapy was acceptable if completed 4 weeks before study
entry.
Exclusion criteria included inadequate liver function (bilirubin
41.5 times above normal range, aspartate transaminase (AST) and
alanine transaminase (ALT) 43 times the normal range, or five
times greater than the normal range in the presence of liver
metastases); severe alteration of renal functionality (serum
creatinine 42  the upper limit of normal (ULN)); no second
malignancies (except for carcinoma of the cervix uteri in situ and
squamous cell carcinoma of the skin); peripheral neuropathy;
untreated superior vena cava syndrome; hypercalcaemia requiring
intravenous (i.v.) treatment; the presence of uncontrolled cardiac
disease, uncontrolled diabetes mellitus, infections or other medical
conditions that could have interfered with the trial.
Written informed consent was obtained from each patient
before entering the study. The study was approved by the local
Ethics Committee and was conducted in accordance with ethical
principles stated in the most recent version of the Declaration of
Helsinki or the applicable guidelines on good clinical practice,
whichever represented the greater protection of the individual.
Treatment plan and dose adjustments
Gemcitabine (Gemzar
s, Eli Lilly and Company, Indianapolis, IN,
USA) 1000mgm
 2 was administered as a 30-min i.v. infusion
on days 1 and 8 of a 21-day cycle. Oxaliplatin (Eloxatin
s, Sanofi-
Synthelabo, Paris, France) 130mgm
 2 was administered as a 2-h
i.v. infusion on day 1, following gemcitabine. All patients were
scheduled to receive at least two cycles of therapy, and up to six
cycles if there was no evidence of disease progression. Treatment
was stopped early in cases of patient refusal, severe toxicity,
documented progressive disease (PD) or pregnancy. Patients with
PD after two or four cycles or with stable disease after four cycles
of chemotherapy were withdrawn from the study. Full supportive
therapy, corticosteroids, anticonvulsants and antibotics were given
as needed. Antiemetic premedication included 5-HT3 antagonists.
No routine use of haematopoietic growth factors was planned. No
prophylactic antibiotics were used. All patients were treated on an
outpatient basis.
Dose adjustments during treatment were based on haemato-
logical and nonhaematological toxicities. On day 1, if neutrophil
count was o1.5 10
9l
 1 and/or platelet count was o100 10
9l
 1,
chemotherapy doses were delayed (for up to 2 weeks) and doses
were reduced by 25% to allow recovery from haematological
toxicity. On day 8, for a neutrophil count o1.0 and/or platelets
o75, the gemcitabine dose was omitted, and the cycle continued
with one gemcitabine dose not given. Patients not recovering from
haematological toxicity (neutrophil count 41.0 and platelets 475)
within 2 weeks were withdrawn from the trial. Doses were reduced
by 25% for any grade 3 nonhaematological toxicity (excluding
nausea, vomiting and alopecia). Treatment was discontinued in the
event of grade 4 or frequent grade 3 nonhaematological toxicity.
For grade 2–4 neurological toxicity, oxaliplatin treatment was
delayed until the patient recovered to grade 1, then the dose was
reduced by 25%. If no recovery to grade 1 was achieved in 3 weeks,
the patient was discontinued from the trial.
For hepatic toxicity, the day-1 gemcitabine dose was reduced by
25% for AST/ALT 1.6 to 5.0  ULN, alkaline phosphatase p5.0 
ULN and bilirubin oULN. Treatment was delayed for up to 2
weeks for AST/ALT 45  ULN or alkaline phosphatase 45 
ULN or bilirubin 4ULN. The day-1 gemcitabine dose was omitted
for a total bilirubin 41.5 ULN. For nephrotoxicity, gemcitabine
doses were reduced by 25% for serum creatinine 41.5–2.0 ULN
and creatinine clearance X50mlmin
 1. Treatment was delayed
for serum creatinine 41.5 UNL and creatinine clearance
o50mlmin
 1 or serum creatinine greater than 42.0 UNL with
any creatinine clearance value.
Baseline and treatment assessments
Pretreatment evaluation included physical examination; KPS;
chest X-ray; brain, thoracic and abdominal computer tomography
scan (CT scan); bronchoscopy (if not performed at the time of
diagnosis); bone scan; electrocardiogram; complete blood count
and blood chemistry with liver function tests and creatinine
clearance. On days 1 and 8, a physical exam (including weight)
was performed, and KPS and blood count were assessed. All
measurable and evaluable lesions were assessed by the same
method used at baseline. Response to therapy was assessed every
two cycles with clinical and/or radiological tumour assessment.
In responding patients, a confirmatory assessment was repeated
after at least 4 weeks, according to the RECIST criteria (Therasse
et al, 2000). Assessment of TtPD was determined by measuring the
time interval from the beginning of treatment until the first
documentation of progression or death due to any cause. Survival
(OS) was determined by measuring the time interval from the
beginning of the treatment to the date of death or last contact.
Toxicity was evaluated according to NCI criteria (Common
Toxicity Criteria, 1993). No quality of life questionnaire was used
in the present study.
Statistical plan
A two-stage design was used for the study. Using the Simon (1989)
hypothesis, assuming a response rate of 40%, a probability of
error of 5% and a power of 90%, a total of 54 patients were to be
enrolled, with at least five responses to be noted in the first 19
patients. Treatment was considered effective if at least 16 objective
responses were observed. Every patient included in the study was
considered evaluable (intent-to-treat analysis). Response rates,
including 95% confidence intervals (CIs), were calculated on an
intent-to-treat basis. Time-to-event end points were calculated
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susing the Kaplan–Meier method, with the appropriate censoring
(Kaplan and Meier, 1958).
RESULTS
Patient characteristics
From February 2002 to May 2004, a total of 60 patients were
enrolled in this trial in seven Italian centres. Patients’ characteris-
tics at baseline are listed in Table 1. The majority of patients were
male (71.7%), with a median age of 61 years (range 36–74).
Performance status was 100 in 46.7% of patients; 51 (85.0%)
patients had stage IV and nine (15.0%) had stage IIIB disease.
Histology was predominantly adenocarcinoma (55.9% of the
patients).
Efficacy
As per the ITT analysis, the ORR was 25.0% (95% CI, 14.7–37.9%),
including one complete response (CR: 1.7%) and 14 partial
responses (PRs: 23.3%, Table 2). Two patients were not assessable
for response because they discontinued the trial after the first
cycle, one for heart attack and the other for cardiac failure; neither
event was related to the study drugs. The median duration of
response was 5.9 months (range 1.5–17.1 months). With a median
follow-up time of 6.7 months, the median TtPD was 2.7 (range
1.9–3.4 months), median OS time was 7.3 months (range 7.2–8.6
months) and 1-year survival was 36% (Figures 1, 2).
Table 1 Baseline patient characteristics (N¼60)
Characteristics No. of patients
Median age (range), years 61 (36–74)
Male/female (%) 43 (71.7)/17 (28.3)
KPS (%)
100 28 (46.7)
90–80 31 (51.7)
70 1 (1.7)
Stage IIIB/IV (%) 9 (15.0)/51 (85.0)
Sites of metastasis
Liver 6
Brain 4
Bone 4
Nodes 22
Others 17
No. of metastatic sites
13 1
X22 0
Histology (%)
Adenocarcinoma 33 (55.0)
Squamous 17 (28.3)
Bronchioloalveolar 1 (1.7)
Undifferentiated 5 (8.3)
Other NSCLC 3 (5.0)
Unknown 1 (1.7)
KPS¼Karnofsky performance status; NSCLC¼non-small-cell lung cancer.
Table 2 Best overall response (N¼60)
Response n (%)
ORR 15 (25.0)
CR 1 (1.7)
PR 14 (23.3)
SD 18 (30.0)
PD 25 (41.7)
Not assessable 2 (3.3)
ORR¼overall response rate; CR¼complete response; PR¼partial response;
SD¼stable disease; PD¼progressive disease.
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Figure 1 Kaplan–Meier curve for progression-free survival.
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Figure 2 Kaplan–Meier curve for OS.
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sTreatment administration
A total of 209 chemotherapy courses were administered, with a
median of 3.9 cycles per patient (range 1–6), and 16 (26.7%)
patients received all six cycles. The planned dose intensity was
666.6mgm
 2week
 1 for gemcitabine and 43.3mgm
 2week
 1 for
oxaliplatin. Dose intensity for all 60 patients was
615mgm
 2week
 1 for gemcitabine and 42.4mgm
 2week
 1 for
oxaliplatin, with 92.3% of the planned gemcitabine dose and 97.9%
of the planned oxaliplatin dose delivered.
Toxicity
The main haematological toxicities (Table 3) were transient grade
3–4 neutropenia observed in seven (11.7%). patients, grade 3–4
thrombocytopenia not requiring platelet transfusion in five
(8.3%) patients and grade 3 anaemia in one (1.7%) patient. No
neutropenic fever or bleeding episodes were recorded. Nonhae-
matological toxicity was generally manageable (Table 4). Grade 3
nausea/vomiting occurred in five (8.3%) and grade 4 occurred
in one (1.7%) patients. Two (3.3%) patients developed grade 3
neurotoxicity requiring oxaliplatin dose reduction. Two (3.3%)
patients had grade 4 cardiovascular toxicity consisting of
extrasystoles and atrial flutter. A total of 25.0% of the patients
displayed grade 1–2 pulmonary symptoms, such as dyspnea, but
this was due to disease progression. Grade 1 nephrotoxicity
occurred in one (1.7%) patient. Two serious adverse events were
reported during the study. One patient died after the first course
due to heart attack and the other patient died due to cardiac
failure. Neither of these deaths was considered treatment-related.
DISCUSSION
Our study confirmed the promising activity and favourable
toxicity profile of gemcitabine–oxaliplatin in patients with stage
IIIB/IV NSCLC. We observed an ORR of 25.0%, with one CR and
14 PRs. The median duration of response was 5.9 months (range
1.5–17.1 months). Median TtPD was 2.7 months (range 1.9–3.4
months) and median OS was 7.3 months (range 7.2–8.6 months).
The 25% ORR observed in the present study seems to be not
different from the 20–22% response rate obtained with gemcita-
bine when used as single agent (Abratt et al, 1994; Gatzemeier et al,
1996). However, although our study population was relatively
young and with good performance status, a large percentage of
stage IV patients was enrolled, including individuals with
unfavourable prognostic factors, such as brain metastases.
Two trials have evaluated the activity and toxicity of gemcita-
bine–oxaliplatin in NSCLC patients (Faivre et al, 2002; Franciosi
et al, 2003). Both trials included pretreated patients, and response
rates ranged from 16 to 34%. The 16% response rate reported in
the Franciosi trial was lower than that reported in our study
(25.0%), probably because our study was conducted only in
chemonaive patients. In the study conducted by Faivre et al.,1 2
of the 35 patients (34.2%) enrolled in the trial responded to the
therapy, including two platinum-resistant patients. These results
are better than those observed in our trial, probably because of the
different characteristics of our cohort, which included a larger
percentage of stage IV disease (85% in our study vs 71%), and a
lower percentage of patients with a performance status of 100
(46.7% in our study vs 85.7%).
The response rate observed with gemcitabine–oxaliplatin in the
present trial was also comparable to the activity of oxaliplatin-
based combinations observed in other phase II studies. Oxaliplatin
has been evaluated in combination with vinorelbine (Monnet et al,
2001) and in combination with taxanes (Winegarden et al, 2004),
producing response rates of 19 and 37%, respectively.
One of the most important findings of our trial is the low
toxicity profile demonstrated by gemcitabine–oxaliplatin. In phase
II trials, single-agent gemcitabine was administered at the dose
of 1000–1250mgm
 2 on days 1, 8 and 15 (Anderson et al, 1994;
Gatzemeier et al, 1996; Le Chevalier et al, 1997), or at the dose
of 1250mgm
 2 on days 1 and 8 when used in combination
with cisplatin (Castellano et al, 1998). Planned dose intensity of
gemcitabine in our study was lower than those reported by others
(Anderson et al, 1994; Gatzemeier et al, 1996; Le Chevalier et al,
1997; Castellano et al, 1998), providing an additional explication
for the excellent toxicity profile demonstrated by this regimen.
We used the 130mgm
 2 dose per cycle for oxaliplatin and
2000mgm
 2 dose per cycle for gemcitabine evaluated in other
reports (Franciosi et al, 2003; Mavroudis et al, 2003), and further
demonstrated that the haematological and nonhaematological
toxicities with this regimen are generally mild or moderate. The
tolerability of the regimen is underscored by the fact that we were
able to deliver full doses of the planned therapy to the majority
of patients. The main grade 3–4 haematological toxicities were
transient neutropenia and thrombocytopenia (11.7 and 8.3% of
patients, respectively). Nausea/vomiting was the main grade 3–4
nonhaematological toxicity, occurring in six (10.0%) patients. Only
two (3.3%) patients developed significant (grade 3) neurotoxicity.
The low incidence of side effects in our trial is of particular
relevance to clinical practice because it suggests that gemcitabine–
oxaliplatin could be used in patients ineligible for standard
platinum-based therapy, such as the elderly or unfit. At the present
time, single-agent therapy is the standard treatment for elderly
or unfit patients (Gridelli et al, 2003), but there is clear evidence
that two-drug combinations are better than single-agent therapy
(Sederholm, 2002; Lilenbaum et al, 2005), and platinum-based
chemotherapy should be considered for selected elderly patients
(Bunn and Lilenbaum, 2003).
In conclusion, our findings further demonstrate that gemcita-
bine–oxaliplatin is active and well tolerated in patients with
advanced NSCLC. The favourable toxicity profile of this regimen
also justifies its use in patients in whom cisplatin may not be
feasible, such as the elderly or unfit. Oxaliplatin hopefully will
Table 3 Worst grade 3–4 NCI haematological toxicity
By patient (N¼60) By cycle (N¼209)
Toxicity
Grade 3
n (%)
Grade 4
n (%)
Grade 3
n (%)
Grade 4
n (%)
Neutropenia 6 (10.0) 1 (1.7) 16 (7.7) 1 (0.5)
Thrombocytopenia 4 (6.7) 1 (1.7) 10 (4.8) 1 (0.5)
Anaemia 1 (1.7) 0 1 (0.5) 0
Leukopenia 1 (1.7) 0 1 (0.5) 0
Table 4 Worst grade 3–4 NCI nonhaematological toxicity
By patient (N¼60) By cycle (N¼209)
Toxicity
Grade
1–2 n (%)
Grade
3–4n (%)
Grade
1–2 n (%)
Grade
3–4 n (%)
Gastrointestinal 37 (61.7) 6 (10.0) 126 (60.3) 9 (4.3)
Neurological 27 (45.0) 2 (3.3) 52 (24.9) 2 (1.0)
Hepatic 17 (28.3) 2 (3.3) 73 (34.9) 2 (1.0)
Dermatological 11 (18.3) 1 (1.7) 12 (5.7) 1 (0.5)
Cardiovascular 7 (11.7) 2 (3.3) 7 (3.3) 2 (1.0)
Pulmonary 15 (25.0) 1 (1.7) 31 (14.8) 1 (0.5)
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sbecome an alternative to cisplatin whose toxicity profile is not
acceptable for many patients with NSCLC. In the era of targeted
therapies, this combination deserves to be studied further in
association with new agents, such as the antivascular endothelial
growth factor bevacizumab, or the monoclonal antibody anti-
epidermal growth factor receptor cetuximab.
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